Near Patient Molecular Testing in Sepsis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

63 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-12

Study Completion Date

2022-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the real-time performance of a new host response test (SeptiCyte RAPID) for differentiating sepsis from non-infection/systemic inflammatory response syndrome among patients suspected of sepsis within the first 24 hours of intensive care unit (ICU) admission.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS

NCT02704871

Sepsis SIRS

TERMINATED

Molecular Early Sepsis Identification Study

NCT05833412

Sepsis Molecular Diagnosis

UNKNOWN

VENUS: Septic Gene Expression Using SeptiCyte

NCT02127502

Sepsis Systemic Inflammatory Response Syndrome (SIRS)

COMPLETED

A Blood Test to Diagnose Sepsis in Symptomatic Adults and Children

NCT05142813

Infections Sepsis SIRS

UNKNOWN

Identification and Clinical Efficacy Analysis of Biomarkers in Sepsis Patients

NCT05911711

Sepsis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The ability of SeptiCyte RAPID to differentiate sepsis from infection-negative systemic inflammation will be determined using retrospective physician diagnosis performed by an external panel of three physicians not involved with the care of the patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Systemic Inflammatory Response Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Critically ill patients sepsis suspected

Patients suspected of sepsis and admitted to ICU

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ≥18 years old on the date of ICU admission
2. Systemic Inflammatory Response Syndrome (SIRS) present, as defined by the presence of two or more of the following:

1. Temperature \> 38°C or \< 36°C
2. Heart Rate \> 90 beat/min
3. Tachypnea \> 20/min or PaCO2 \< 32 mmHg
4. WBC count \> 12 000/mm3 or \< 4 000/mm3 or \> 10% immature neutrophils (bands)
3. Consent to study inclusion, either by patient or legal surrogate before study-related sample processing
4. Study sample collection within 24 hours of ICU admission order

Exclusion Criteria

1. Age less than 18 years old on the day of ICU admission
2. No order to admit to ICU
3. Not physically admitted to ICU
4. Commencement of non-prophylactic antibiotics ≥ 24 hours prior to ICU admission
5. Study sample collection \> 24 hours from ICU admission order
6. No clinical cultures or serologic tests obtained when sepsis was suspected
7. Elective cardiac surgery patients with an expected duration in ICU of less than 24 hours
8. Transfer from another ICU where subject was admitted for ≥ 24 hours.

Minimum Eligible Age

18 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No